ArticleFrontiers in pediatrics2026
Case Report: Torque teno virus identified in pleural effusion of pediatric severe Mycoplasma pneumoniae pneumonia: diagnostic and therapeutic implications.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae pneumonia (MPP) is a common cause of community-acquired pneumonia (CAP) in school-aged children, among whom 1%-20% may develop pleural effusion. Most effusions are small in volume and self-resolving. We report two pediatric cases of severe MPP complicated by massive pleural effusion that were unresponsive to initial anti-mycoplasma therapy. Targeted next-generation sequencing (tNGS) of pleural fluid identified macrolide-resistant Mycoplasma pneumoniae and Torque teno virus (TTV) in both cases. Both patients recovered after closed thoracic drainage, adjustment of anti-mycoplasma therapy according to resistance findings, and adjunctive immunomodulatory treatment. These cases indicate that, in severe MPP with massive pleural effusion, pleural-fluid tNGS may provide useful diagnostic information beyond conventional testing, including the identification of macrolide resistance and additional viral findings such as TTV. However, given the high background prevalence of TTV in humans and the absence of control samples in this report, the clinical significance of TTV detection in pleural fluid remains uncertain. At present, TTV is more appropriately interpreted as a possible biomarker of immune perturbation or disease severity rather than a confirmed pathogenic driver. Broader pathogen testing in selected specimens such as pleural fluid may complement diagnostic evaluation in complex infections, but larger controlled studies are needed to clarify the significance of TTV in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.